2nd Congress on Congenital Cytomegalovirus 2021

Description Include: 8 videos 1 pdf, size: 25.1 GB Target Audience: pediatricians, infectious disease specialists, obstetricians/gynecologists Sample video: contact me for sample video Information: CMV 2021 2nd Congress on Congenital CMV 21 – 22 OCTOBER 2021 Rome, Italy Scientific Goal The most prevalent congenital infection and the first cause of non genetic hearing loss continues to be largely ignored or misunderstood outside expert circles. We invite all care providers to attend this meeting to meet the experts and improve their practice for a better outcome. Congress Topics The risks in pregnancy are well defined Screening and diagnostic tools are efficient, and quality control is effective Primary prevention is part of preconceptional medicine Vaccine technology has been revolutionized by the COVID pandemic Diagnosis is as reliable prenatally and postnatally Secondary and tertiary prevention are efficient and should be widely implemented Postnatal care has been simplified and rationalized Sensorineural hearing loss is not a fatality Are there any late complications other than hearing impairment is asymptomatic children? Sensorineural hearing loss is not a fatality Hearing rehabilitation in cCMV children with unilateral hearing loss Is there an association between CMV infections and ADD/Autism/Schizophrenia? Brain imaging for children with cCMV – Ultrasound or MRI? Universal screening for cCMV Early diagnosis of cCMV using Chorionic villus sampling Vestibular problems in symptomatic and asymptomatic cCMV What can we offer to asymptomatic children with late onset hearing loss? The 2nd Congress on Congenital Cytomegalovirus 2021 was aimed at a diverse group of healthcare professionals involved in the care and research of congenital cytomegalovirus (CMV). The target audience included: Pediatricians Infectious Disease Specialists Obstetricians/Gynecologists Nurses and Nurse Practitioners Physician Assistants Researchers and Scientists in the field of CMV and related areas This event provided a platform for these professionals to discuss the latest research, clinical practices, and advancements in the understanding and management of congenital CMV.   Topics: 1 Welcome and SESSION 1 – Asymptomatic children with cCMV.mp4 2 Debate 1 UNIVERSAL NEONATAL SCREENING.mp4 3 SESSION 2 – Infection during pregnancy.mp4 4 DEBATE Vaccines – adults or toddlers.mp4 5 SESSION 4 Fetal infection.mp4 6 DEBATE Invasive Diagnosis the earlier the better.mp4 7 SESSION 5 – Hearing loss, vestibular disorders and rehabilitation in children with cCMV and Closing.mp4 8 Congenital CMV infection how to implement the diagnostics and the clinical follow up.mp4 Program.pdf   * Detail: 21 October 09:00-09:05 WELCOME FROM CONGRESS PRESIDENTS Yves Ville, France 09:05-12:15 SESSION 1 – Asymptomatic children with cCMV Moderators: Daniel Blázquez Gamero, Spain – Efraim Bilavsky, Israel 09:05-09:25 What is an asymptomatic neonate in 2021? Daniel Blázquez Gamero, Spain 09:25-09:45 What can we offer to asymptomatic children with late onset hearing loss? Ina Foulon, Belgium 09:45-10:05 Advanced imaging in fetal CMV infection Chloe Arthuis, France  10:05-10:15 Panel Discussion 10:15-10:25 (ID 11) – Does universal newborn screening for congenital cytomegalovirus (cCMV) infection help? A cohort study from Qatar and Germany Katrin Neumann, Germany 10:25-10:35 (ID 12) – Congenital CMV infection: a risk factor for neuro-psychological sequelae? Arianna Turriziani Colonna, Italy 10:35-10:45 (ID 48) – Congenital CMV infection – 7 years experience in a Portuguese neonatal intensive care unit Francisca Calheiros Trigo, Portugal 10:45-11:00 Discussion 11:00-11:30 COFFEE BREAK 11:30-11:40 (ID 16) Evolution of the intracranial features of congenital CMV in children Jack Garnham, United Kingdom 11:40-11:50 (ID 42) Single Nucleotide Polymorphisms of Interleukins and Toll-like Receptors and Neuroimaging Results in Newborns with Congenital HCMV Infection Justyna Czech-Kowalska, Poland 11:50-12:00 (ID 47) Newborns with Autism Spectrum Disorder: a link with congenital CMV? Perrine Coste Mazeau, France 12:00-12:15 Discussion 12:15-13:00 DEBATE: UNIVERSAL NEONATAL SCREENING Mark R. Schleiss, USA Vs. Daniel Blázquez Gamero, Spain 13:00-14:00 LUNCH / POSTER VIEWING 14:00-15:00 Congenital CMV infection: how to implement the diagnostics and the clinical follow up industry supported session 15:00-15:35 ORAL COMMUNICATION Congenital CMV infection 15:00-15:10 (ID 31) – Prevalence and Clinical Characteristics of Congenital Cytomegalovirus Infection in a Population-Based Universal Newborn Screening Study in Minnesota Mark Schleiss, United States 15:10-15:20 (ID 35) – Screening for congenital cytomegalovirus in preterm babies <30 weeks gestation Helen Payne, United Kingdom 15:20-15:35 Discussion 15:35-16:00 COFFEE BREAK 16:00-17:30 SESSION 2 – Infection during pregnancy Moderators: Tiziana Lazzaroto, Italy 16:00-16:20 Gestational age at maternal infection and postnatal outcome Christos Chatzakis, Greece 16:20-16:40 The biological clock for maternal serology is ticking for prenatal screening Marianne Leruez, France 16:40-17:00 Non-primary infections. Biological markers Daniele Lilleri, Italy 17:00-17:10 (ID 8) – Cytomegalovirus non primary infection during pregnancy: retrospective serological and molecular analysis in 38 patients. Claire Perillaud-Dubois, France 17:10-17:20 (ID 36) – CMV DNA in placentae from first trimester primary infection cases with or without fetal infection and with or without valaciclovir treatment Jacques Fourgeaud, France 17:20-17:30 Discussion 17:30-18:30 DEBATE: Vaccines – adults or toddlers? Yves Ville, France vs Efraim Bilavsky, Israel 22 October 09:00-12:00 SESSION 4 Fetal infection Moderators: Karl Oliver Kagan, Germany 09:00-09:20 International registry on the use of valaciclovir for secondary prevention Valentine Faure-Bardon, France 09:20-09:40 Hyperimmune globulins, how and how much Karl Oliver Kagan, Germany 09:40-10:00 Screening in pregnancy, what can you get for your money? Valérie Seror, France 10:00-10:20 Screening in pregnancy, why not then? Anna Gonce, Spain 10:20-10:45 Discussion 10:45-11:15 COFFEE BREAK 11:15-12:00 DEBATE: Invasive Diagnosis the earlier the better Yves Ville, France Vs. Schlomo Lipitz, Israel 12:00-12:20 Do we need to perform brain MRI in every infant with Ccmv? Efi Bilavsky, Israel 12:20-13:30 LUNCH AND POSTER VIEWING 13:30-16:15 SESSION 5 – Hearing loss, vestibular disorders and rehabilitation in children with cCMV Moderators: Ina Foulon, Belgium 13:00-13:20 Hearing loss in children with cCMV – from the broad spectrum to the individual Blake Papsin, Canada 13:20-13:40 How do we diagnose and treat vestibular problems in children with CCMV? Natacha Teissier, France 13:40-14:00 Hearing and vestibular rehabilitation in children with unilateral hearing loss Blake Papsin, Canada 14:00-14:15 Discussion 14:15-14:25 (ID 10) – The CONCERT Study: Treatment of Infants with Congenital Cytomegalovirus Infection and Isolated Hearing Loss, Detected Through Newborn Hearing Screening P.K. Chung, the Netherlands 14:25-14:35 (ID 4) – The effect of (val)ganciclovir on hearing in congenital cytomegalovirus: a systematic review. Elise De Cuyper, Belgium 14:35-14:45 (ID 40) – Immunogenicity Findings From a Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an mRNA- Based Vaccine Against Cytomegalovirus Infection Lori Panther, United States 14:45-14:55 (ID 43) – Universal newborn screening for congenital CMV infection: a prospective multicenter clinical trial Liliana Gabrielli, Italy 14:55-15:05 (ID 49) – Prognostic value of mild cerebral features in infected fetuses treated in utero after maternal infection in the first trimester N BOURGON, France 15:05-15:30 COFFEE BREAK 15:30-15:40 (ID 18) – Unmet needs in maternal diagnosis and treatment for congenital CMV in France: data from the French “congenital CMV declaration platform” of the National Reference Center for Herpesviruses Elodie Ribot, France 15:40-15:50 (ID 22) Cortical maturation assessed by magnetic resonance imaging in unaffected/mildly affected fetuses with cytomegalovirus infection. Ameth Hawkins-Villarreal, Spain 15:50-16:00 (ID 23) Performance of targeted congenital cytomegalovirus screening in newborns failing universal hearing screening: a multicenter study Jacques Fourgeaud, France 16:00-16:15 Discussion 16:15-16:45 Anti-CMV Vaccines. Any lesson learned from the Covid pandemic? Shilpe Sharma, Belgium 16:45-17:00 CLOSING REMARKS Yves Ville, Efraim Bilavsky